SSc in 2011: From mechanisms to medicines

Nature Reviews Rheumatology

Volumn 8, Issue 2, 2012, Pages 72-74

  Mouthon, Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DASATINIB; ENDOTHELIN 1; GAMMA INTERFERON; IMATINIB; NILOTINIB; PENICILLAMINE; PROTEINASE ACTIVATED RECEPTOR 1; RELAXIN; SEROTONIN 2B RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

CELL ACTIVATION; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXTRACELLULAR MATRIX; FATIGUE; FLUID RETENTION; HUMAN; INTRACELLULAR SIGNALING; LUNG FIBROSIS; MOLECULAR PATHOLOGY; MORBIDITY; MYOFIBROBLAST; NAUSEA AND VOMITING; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SKIN FIBROSIS; SYNCOPE; SYSTEMIC SCLEROSIS; UPREGULATION; WEAKNESS;

BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; FIBROSIS; HUMANS; MOLECULAR TARGETED THERAPY; PIPERAZINES; PLATELET ACTIVATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84856594778     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.203     Document Type: Review

References (10)

1. Bhattacharyya, S., Wei, J. & Varga, J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. http://dx.doi.org/10.1038/nrrheum.2011.149.
2. Distler, J. H. & Distler, O. Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford) 48, 2-4 (2009).
3. Aono, Y. et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 171, 1279-1285 (2005). (Pubitemid 40740736)
4. Distler, J. H. et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56, 311-322 (2007). (Pubitemid 46106205)
5. Spiera, R. F. et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann. Rheum. Dis. 70, 1003-1009 (2011).
6. Khanna, D. et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 63, 3540-3546 (2011).
7. Pope, J. et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 63, 3547-3551 (2011).
8. Chrysanthopoulou, A. et al. Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A. Arthritis Rheum. 63, 3586-3597 (2011).
9. Dees, C. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 208, 961-972 (2011).
10. Postlethwaite, A. E. & Chiang, T. M. Platelet contributions to the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 19, 574-579 (2007). (Pubitemid 47530878)